Enquire now

Please fill out the form below and we'll do our best to contact you within the next working day.

Please fill in your name (atleast three characters long)
Please add a message
Please tell us how you heard about us.

Other contacts

You can call us Monday to Friday, between 9:15 am – 5:15 pm Central European Time.


Processing.

We are handling your request.

Success!

We received your message! Thank you for contacting us.

Oops!

Something went wrong, please try again.

Ocrevus (ocrelizumab)

How to buy Ocrevus:
You can order Ocrevus (ocrelizumab) via TheSocialMedwork if the drug has not been approved and/or is not available in the patient’s country. TheSocialMedwork – helping patients and doctors access the latest approved medicines and at the lowest price possible worldwide.

Manufacturer Roche
Disease Multiple Sclerosis
Indication Relapsing or primary progressive forms of multiple sclerosis
Mode of action Monoclonal antibody (immunotherapy)
Approval Status FDA Approved (USA)
TGA Approved (AUS)
Shipping Type Cold Chain (2°C to 8°C)

Who is ocrelizumab for?

Ocrevus (ocrelizumab) is indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis [1][4].

Recommended dose

Complete information about Ocrevus (ocrelizumab) dosage and administration can be found here: [1][4].

The standard dosage is:

  • Start dose: 300 mg intravenous infusion, followed two weeks later by a second 300 mg intravenous infusion
  • Subsequent doses: 600 mg intravenous infusion every 6 months.

Patients should be monitored closely during and for at least one hour after infusion as infusion reactions may be possible.

Consult your treating doctor for personalised dosing.

What is ocrelizumab and how does it work?

Ocrevus (ocrelizumab) is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis (MS) [1][4]. It is the first approved treatment for the primary progressive form of MS [2].

MS is a chronic, inflammatory, autoimmune disease that affects the central nervous system, and in particular the communication between the brain and other parts of the body [2]. The patient’s own immune system is supposed to be the cause of the damage to neurons [3]. In its relapsing form, MS is characterized by episodes of worsening function (relapses) which are initially followed by recovery periods (remissions). In its primary progressive form, MS is characterized by steadily worsening function from the onset of symptoms, often without early relapses or remissions [2].

The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to bind to a type of antigen, named CD20, found on the surface of some antibodies (pre-B and mature B lymphocytes) and induce their death [2]. In this way, it is supposed to prevent these antibodies from damaging neurons.

What is ocrelizumab’s approval status?

Ocrevus (ocrelizumab) was approved by:

  • FDA (USA) on March 28, 2017

for the treatment of adults with relapsing or primary progressive forms of multiple sclerosis [2].

The approval of Ocrevus (ocrelizumab) for relapsing forms of multiple sclerosis (RMS) was based on two randomized, double-blind clinical trials of identical design in patients with RMS who were treated for 96 weeks. In both studies, ocrelizumab was compared to another medicine for RMS named interferon beta-1a. In study 1, 410 patients received ocrelizumab and 411 received the interferon beta-1a, while in study 2 the distrubution of patients in the two groups was 417 and 418, respectively [1][4].

In both studies, the patients receiving ocrelizumab had reduced relapse rates and reduced worsening of disability compared to interferon beta-1a. Patients treated with ocrelizumab had a reduction in the annualized relapse rate of 46 % in study 1 and 47 % in study 2, with a proportion of relapse-free of 83 % (vs. 71% in the group treated with interferon beta-1a) in study 1, and 82 % (vs. 72 %) in study 2. The risk of disability progression was reduced by 40 % in the ocrelizumab arm. Disability progression was defined as an increase of 1.0 point or more from the baseline Expanded Disability Status Scale (EDSS) score for patients with baseline score of 5.5 or less, or 0.5 or more when the baseline score is greater than 5.5 at week 96. Moreover, the number of enlarged or new lesions was substantially less in the ocrelizumab group: the relative reduction of the mean number of new and/or enlarging lesions was around 95 % with one type of measure (T1 Gd-enhancing lesions) and about 80 % with another type of measure (new and/or enlarging T2 hyperintense lesions) [1][4].

The approval of Ocrevus (ocrelizumab) for primary progressive multiple sclerosis (PPMS) was based on one randomized, double-blind clinical trial in which ocrelizumab (488 patients) was compared to placebo (244 patients).

The percentage of patients on ocrelizumab who had confirmed disability progression was 32.9 % versus 39.3 % of those on placebo, which accounts for a risk reduction of 24 %. Disability progression was defined as an increase of 1.0 point or more from the baseline Expanded Disability Status Scale (EDSS) score for patients with baseline score of 5.5 or less, or 0.5 or more when the baseline score is greater than 5.5. The mean change in the volume of lesions at week 120 was -0.39 with ocrelizumab and 0.79 with placebo [1][4].

References

[1] Summary of Product Characteristics [FDA]: Ocrevus (ocrelizumab), Genentech, Mar. 2017.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf

[2] FDA News Release: FDA approves new drug to treat multiple sclerosis, 29/09/2017.https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm549325.htm

[3] Wikipedia. Multiple sclerosis, (last update: 31/03/2017), cited on 19/05/21017.https://en.wikipedia.org/wiki/Multiple_sclerosis

[4] Summary of Product Characteristics [TGA]: Ocrevus (ocrelizumab), Roche, July 2017.https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2017-PI-02089-1

Strength
Package Size
VAT
Quantity
Subtotal
8,356.938,858.35
Clear Selections
Handling Fee €295
Shipping Options

Shipping Cost Estimate
Total
Clear Selections
How to order an overseas approved medicine from TheSocialMedwork.

Ordering with TheSocialMedwork is a safe and legal way to import a prescription medicine that has been approved in another country, but is not yet available where you live.

1. Enquire

If you think that this medicine may be suitable for treating your condition, get in touch. We’ll answer any questions you might have and provide you with further information. Click on the calculate price tab to get a close estimate of the full cost of the medicine including delivery. If you would like us to provide you with a precise quote we’ll need to know the exact address of where you would like us to send your medicine to.

2. Chat with your doctor

About whether this treatment might be suitable for you. In order to place an order with us, you’ll need to provide us with a prescription from your doctor who must be based in the same country where the medicine will be shipped to.

3. Place your order

Once you have your doctor’s prescription you’re ready to place an order with us. Payment can be made by credit card, electronic bank transfer or paypal.

4. Delivery

As soon as we receive your payment we’ll process your order and your medicine will be shipped to you via a pharmacy. Delivery time can vary from country to country but usually takes 1 to 3 weeks. We’ll send you a tracking number and keep you up to date on the status of your order.

 

Rest assured that we’ll guide you through the entire process. We’ll let you know exactly what regulations need to be followed and the specific documentation you’ll need to import the medicine into your country so that you get your treatment as quickly as possible.

Ask us a question
Simple Share Buttons